← Back to Clinical Trials
Recruiting NCT07425249

NCT07425249 Impact of Chewing Gum on Postoperative Gut Motility in Gastrointestinal Surgery Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07425249
Status Recruiting
Phase
Sponsor Khyber Medical University Peshawar
Condition Postoperative Ileus
Study Type INTERVENTIONAL
Enrollment 96 participants
Start Date 2026-01-01
Primary Completion 2026-08-25

Eligibility & Interventions

Sex All sexes
Min Age 17 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Chewing Gum

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 96 participants in total. It began in 2026-01-01 with a primary completion date of 2026-08-25.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Postoperative ileus (POI) is a frequent complication after abdominal surgery, leading to delayed gastrointestinal motility, prolonged hospital stay, and increased patient discomfort. Chewing gum, as a form of sham feeding, has been proposed to stimulate gut motility through vagal stimulation and increased gastrointestinal secretions. This randomized controlled trial aims to assess the effect of chewing gum on early recovery of gastrointestinal motility in patients undergoing open gastrointestinal surgery.

Eligibility Criteria

Inclusion Criteria: * Age between 17 and 85 years. * Patients of either gender. * Undergoing open gastrointestinal surgical procedures (elective or emergency). * Willing to participate and able to provide informed consent. Exclusion Criteria: * Patients with metabolic or endocrine disorders (diabetes mellitus, hypothyroidism, or hyperthyroidism). * Patients with renal disease or electrolyte imbalance. * Patients with chronic constipation or neuromuscular disorders. * Patients with substance abuse or drug addiction. * Patients receiving medications affecting gut motility (calcium channel blockers or antiepileptic drugs). * Patients with dental prosthesis or undergoing laparoscopic gastrointestinal surgery.

Contact & Investigator

Central Contact

Dr Ali Raza, MBBS

✉ dralicenna022@gmail.com

📞 +923452479895

Principal Investigator

Dr Ali Raza, MBBS

PRINCIPAL INVESTIGATOR

Khyber Teaching Hospital

Frequently Asked Questions

Who can join the NCT07425249 clinical trial?

This trial is open to participants of all sexes, aged 17 Years or older, up to 85 Years, studying Postoperative Ileus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07425249 currently recruiting?

Yes, NCT07425249 is actively recruiting participants. Contact the research team at dralicenna022@gmail.com for enrollment information.

Where is the NCT07425249 trial being conducted?

This trial is being conducted at Peshawar, Pakistan.

Who is sponsoring the NCT07425249 clinical trial?

NCT07425249 is sponsored by Khyber Medical University Peshawar. The principal investigator is Dr Ali Raza, MBBS at Khyber Teaching Hospital. The trial plans to enroll 96 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology